How to Manage Venous Thromboembolism Risk during Pregnancy in Patients with Inherited Antithrombin Deficiency?

Abstract

Inherited antithrombin deficiency (ATD) is associated with a high risk of venous thromboembolic complications. Association of ATD with other conditions such as pregnancy obviously increases thromboembolic risk and may require anticoagulant therapy for prevention. Although there are several/heterogenous international guidelines regarding thromboprophylaxis in pregnant patients with ATD, data on anticoagulant prophylaxis in this context are scarce in the literature. Thus, this situation remains a challenge both in the antepartum period and during delivery. Physicians from the French Society of Thrombosis and Haemostasis (SFTH) performed a review of the literature to suggest propositions regarding the management of thrombosis prevention based on anticoagulation and antithrombin substitution in ATD pregnant women. In this review, after reporting the thrombotic risk associated with ATD, the indication of anticoagulant therapy, its dosing regimen and monitoring, and the indication of antithrombin concentrates during pregnancy and the postpartum period are discussed as well as peripartum management. Finally, this work confirms the complex management of thrombotic prevention in pregnant patients with ATD. Indeed, it requires to take into account a multiplicity of features cited in our propositions that will hopefully provide some help in this field. This work also highlights the importance of multidisciplinary discussions for pregnant women with ATD who should be counseled in an expert center including hematologist, obstetrician, and anesthetist to optimize their management.

Keywords

pregnancy - antithrombin deficiency - venous thrombosis - thromboprophylaxis

Publication History

Received: 17 February 2025

Accepted: 07 July 2025

Accepted Manuscript online:
08 July 2025

Article published online:
24 July 2025

• References

• 1 Saucedo M, Deneux-Tharaux C. pour le comité national d'experts sur les mort maternelles (CNEMM). [Maternal mortality in France, 2016-2018, frequency, causes and women's profile] Gynecol Obstet Fertil Senol 2024; 52 (04) 185-200
• 2 Brenner B. Haemostatic changes in pregnancy. Thromb Res 2004; 114 (5-6): 409-414
• 3 Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med 2008; 359 (19) 2025-2033
• 4 Kamel H, Navi BB, Sriram N, Hovsepian DA, Devereux RB, Elkind MSV. Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med 2014; 370 (14) 1307-1315
• 5 Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv 1999; 54 (04) 265-271
• 6 James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006; 194 (05) 1311-1315
• 7 Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton III LJ. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143 (10) 697-706
• 8 Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000; 83 (05) 657-660
• 9 Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162 (10) 1182-1189
• 10 Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE study cohort. Am J Med 2013; 126 (09) 832.e13-832.e21
• 11 Chauleur C, Quenet S, Varlet MN. et al. Feasibility of an easy-to-use risk score in the prevention of venous thromboembolism and placental vascular complications in pregnant women: a prospective cohort of 2736 women. Thromb Res 2008; 122 (04) 478-484
• 12 Croles FN, Nasserinejad K, Duvekot JJ, Kruip MJ, Meijer K, Leebeek FW. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis. BMJ 2017; 359: j4452
• 13 Rhéaume M, Weber F, Durand M, Mahone M. Pregnancy-related venous thromboembolism risk in asymptomatic women with antithrombin deficiency: a systematic review. Obstet Gynecol 2016; 127 (04) 649-656
• 14 Tait RC, Walker ID, Perry DJ. et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87 (01) 106-112
• 15 Pabinger I, Brücker S, Kyrle PA. et al. Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coagul Fibrinolysis 1992; 3 (05) 547-553
• 16 Di Minno MND, Ambrosino P, Ageno W, Rosendaal F, Di Minno G, Dentali F. Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies. Thromb Res 2015; 135 (05) 923-932
• 17 Corral J, de la Morena-Barrio ME, Vicente V. The genetics of antithrombin. Thromb Res 2018; 169: 23-29
• 18 Alhenc-Gelas M, Plu-Bureau G, Hugon-Rodin J, Picard V, Horellou MH. GFHT study group on Genetic Thrombophilia. Thrombotic risk according to SERPINC1 genotype in a large cohort of subjects with antithrombin inherited deficiency. Thromb Haemost 2017; 117 (06) 1040-1051
• 19 Van Cott EM, Orlando C, Moore GW, Cooper PC, Meijer P, Marlar R. Subcommittee on Plasma Coagulation Inhibitors. Recommendations for clinical laboratory testing for antithrombin deficiency; communication from the SSC of the ISTH. J Thromb Haemost 2020; 18 (01) 17-22
• 20 Pabinger I, Schneider B. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Arterioscler Thromb Vasc Biol 1996; 16 (06) 742-748
• 21 Buchanan GS, Rodgers GM, Ware Branch D. The inherited thrombophilias: genetics, epidemiology, and laboratory evaluation. Best Pract Res Clin Obstet Gynaecol 2003; 17 (03) 397-411
• 22 Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA. Subcommittees on Control of Anticoagulation, and Predictive and Diagnostic Variables in Thrombotic Disease. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 2016; 14 (07) 1480-1483
• 23 Mushunje A, Zhou A, Carrell RW, Huntington JA. Heparin-induced substrate behavior of antithrombin Cambridge II. Blood 2003; 102 (12) 4028-4034
• 24 Bereczky Z, Gindele R, Fiatal S. et al. Age and origin of the founder antithrombin Budapest 3 (p.Leu131Phe) mutation; its high prevalence in the Roma population and its association with cardiovascular diseases. Front Cardiovasc Med 2021; 7: 617711
• 25 Kuhle S, Lane DA, Jochmanns K. et al. Homozygous antithrombin deficiency type II (99 Leu to Phe mutation) and childhood thromboembolism. Thromb Haemost 2001; 86 (04) 1007-1011
• 26 De Stefano V, Leone G, Mastrangelo S. et al. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994; 71 (06) 799-800
• 27 Abbattista M, Gianniello F, Novembrino C. et al. Risk of pregnancy-related venous thromboembolism and obstetrical complications in women with inherited type I antithrombin deficiency: a retrospective, single-centre, cohort study. Lancet Haematol 2020; 7 (04) e320-e328
• 28 Brouwer JLP, Veeger NJGM, Kluin-Nelemans HC, van der Meer J. The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes. Ann Intern Med 2006; 145 (11) 807-815
• 29 Folkeringa N, Brouwer JLP, Korteweg FJ, Veeger NJGM, Erwich JJHM, van der Meer J. High risk of pregnancy-related venous thromboembolism in women with multiple thrombophilic defects. Br J Haematol 2007; 138 (01) 110-116
• 30 Kovac M, Mitic G, Mikovic Z. et al. The influence of specific mutations in the AT gene (SERPINC1) on the type of pregnancy related complications. Thromb Res 2019; 173: 12-19
• 31 Jukic AM, Baird DD, Weinberg CR, McConnaughey DR, Wilcox AJ. Length of human pregnancy and contributors to its natural variation. Hum Reprod 2013; 28 (10) 2848-2855
• 32 Le Ray C, Lelong N, Cinelli H, Blondel B. Collaborators - Members of the ENP2021 Study Group. Results of the 2021 French National Perinatal Survey and trends in perinatal health in metropolitan France since 1995. J Gynecol Obstet Hum Reprod 2022; 51 (10) 102509
• 33 Grobman WA, Rice MM, Reddy UM. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network. Labor induction versus expectant management in low-risk nulliparous women. N Engl J Med 2018; 379 (06) 513-523
• 34 Sentilhes L. [Induction of labor after prior cesarean delivery: a reasonable option?]. Gynécol Obstét Fertil 2009; 37 (05) 452-453
• 35 Sentilhes L, Vayssière C, Beucher G. et al. Delivery for women with a previous cesarean: guidelines for clinical practice from the French College of Gynecologists and Obstetricians (CNGOF). Eur J Obstet Gynecol Reprod Biol 2013; 170 (01) 25-32
• 36 Ricbourg A, Brugier C, Mezzadri M. et al. Déclenchement artificiel et direction du travail. Obstétrique 2012; 35 (02) 1-17
• 37 Sentilhes L, Vayssière C, Deneux-Tharaux C. et al. Postpartum hemorrhage: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF): in collaboration with the French Society of Anesthesiology and Intensive Care (SFAR). Eur J Obstet Gynecol Reprod Biol 2016; 198: 12-21
• 38 Driessen M, Bouvier-Colle MH, Dupont C, Khoshnood B, Rudigoz RC, Deneux-Tharaux C. Pithagore6 Group. Postpartum hemorrhage resulting from uterine atony after vaginal delivery: factors associated with severity. Obstet Gynecol 2011; 117 (01) 21-31
• 39 Petitprez K, Mattuizzi A, Guillaume S. et al. Normal delivery: physiologic support and medical interventions. Guidelines of the French National Authority for Health (HAS) with the collaboration of the French College of Gynecologists and Obstetricians (CNGOF) and the French College of Midwives (CNSF). J Matern Fetal Neonatal Med 2022; 35 (25) 6576-6585
• 40 Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. . VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012. ;141(2):691–736
• 41 Chan WS, Rey E, Kent NE. et al; VTE in Pregnancy Guideline Working Group, Society of Obstetricians and Gynecologists of Canada. Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can 2014; 36 (06) 527-553
• 42 Nelson-Piercy C, MacCallum A, MacKillop L. Reducing the Risk of Venous Thromboembolism in Pregnancy and the Puerperium. Green-Top Guidelines. Royal College of Obstetricians & Gynaecologists; 2015
• 43 American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 196: thromboembolism in pregnancy. Obstet Gynecol 2018; 132 (01) e1-e17
• 44 Bates SM, Rajasekhar A, Middeldorp S. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv 2018; 2 (22) 3317-3359
• 45 Hart C, Bauersachs R, Scholz U. et al. Prevention of venous thromboembolism during pregnancy and the puerperium with a special focus on women with hereditary thrombophilia or prior VTE—position paper of the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH). Hamostaseologie 2020; 40 (05) 572-590
• 46 Bramham K, Retter A, Robinson SE, Mitchell M, Moore GW, Hunt BJ. How I treat heterozygous hereditary antithrombin deficiency in pregnancy. Thromb Haemost 2013; 110 (03) 550-559
• 47 Hart C, Rott H, Heimerl S, Linnemann B. Management of antithrombin deficiency in pregnancy. Hamostaseologie 2022; 42 (05) 320-329
• 48 Fiskvik H, Jacobsen AF, Iversen N, Henriksson CE, Jacobsen EM. Treatment of homozygous type II antithrombin heparin-binding site deficiency in pregnancy. Case Rep Obstet Gynecol 2021; 2021: 4393821
• 49 Komori M, Hayata E, Nakata M, Yuzawa H, Oji A, Morita M. Apixaban therapy in a pregnant woman with heparin-induced thrombocytopenia and venous thromboembolic events caused by congenital antithrombin deficiency: a case report. Case Rep Womens Health 2020; 27: e00200
• 50 Hisano M, Mitsui M, Sago H, Yamaguchi K. Thromboprophylaxis with antithrombin gamma and unfractionated heparin for a pregnant woman complicated by hereditary antithrombin deficiency. Int J Gynaecol Obstet 2020; 148 (02) 263-264
• 51 Skeith L, Aw A, Hews-Girard J, Rydz N. A case that illustrates the challenges of managing pregnant patients with antithrombin deficiency: more questions than answers. Thromb Res 2017; 157: 1-6
• 52 Refaei M, Xing L, Lim W, Crowther M, Boonyawat K. Management of venous thromboembolism in patients with hereditary antithrombin deficiency and pregnancy: case report and review of the literature. Case Rep Hematol 2017; 2017: 9261351
• 53 Kovac M, Mitic G, Miljic P. et al. Poor pregnancy outcome in women with homozygous type-II HBS antithrombin deficiency. Thromb Res 2014; 133 (06) 1158-1160
• 54 Kovac M, Mitic G, Mikovic Z. et al. Pregnancy related stroke in the setting of homozygous type-II HBS antithrombin deficiency. Thromb Res 2016; 139: 111-113
• 55 Rogenhofer N, Bohlmann MK, Beuter-Winkler P. et al. Prevention, management and extent of adverse pregnancy outcomes in women with hereditary antithrombin deficiency. Ann Hematol 2014; 93 (03) 385-392
• 56 Pearson-Stuttard B, Bagot C, Ciantar E. et al. Severe antithrombin deficiency in pregnancy: achieving adequate anticoagulation. Obstet Med 2019; 12 (01) 45-51
• 57 Bistervels IM, Buchmüller A, Wiegers HMG. et al; Highlow Block Writing Committee, Highlow Investigators. Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial. Lancet 2022; 400 (10365): 1777-1787
• 58 Roberts JC, von Drygalski A, Zhou JY, Rodgers GM, Ansteatt K, Tarantino MD. Five challenging cases of hereditary antithrombin deficiency characterized by thrombosis or complicated pregnancy. J Blood Med 2022; 13: 611-618
• 59 Tsikouras P, Christoforidou A, Bothou A. et al. Overcoming heparin resistance in pregnant women with antithrombin deficiency: a case report and review of the literature. J Med Case Rep 2018; 12 (01) 169
• 60 Fuchs F, Benhamou D. Césarienne et post-partum. Recommandations pour la pratique clinique. J Gynecol Obstet Biol Reprod (Paris) 2015; 44 (10) 1111-1117
• 61 Rosenberg RD. Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. Am J Med 1989; 87 (3B): 2S-9S
• 62 Kjaergaard AB, Fuglsang J, Hvas AM. Anti-Xa monitoring of low-molecular-weight heparin during pregnancy: a systematic review. Semin Thromb Hemost 2021; 47 (07) 824-842
• 63 Newall F. Anti-factor Xa (anti-Xa) assay. Methods Mol Biol 2013; 992: 265-272
• 64 Ignjatovic V, Summerhayes R, Gan A. et al. Monitoring unfractionated heparin (UFH) therapy: which anti-factor Xa assay is appropriate?. Thromb Res 2007; 120 (03) 347-351
• 65 Hardy M, Cabo J, Deliège A. et al. Reassessment of dextran sulfate in anti-Xa assay for unfractionated heparin laboratory monitoring. Res Pract Thromb Haemost 2023; 7 (08) 102257
• 66 Bounameaux H, de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J Thromb Haemost 2004; 2 (04) 551-554
• 67 Kearon C, Ginsberg JS, Julian JA. et al; Fixed-Dose Heparin (FIDO) Investigators. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006; 296 (08) 935-942
• 68 Whitman-Purves E, Coons JC, Miller T. et al. Performance of anti-factor Xa versus activated partial thromboplastin time for heparin monitoring using multiple nomograms. Clin Appl Thromb Hemost 2018; 24 (02) 310-316
• 69 Kitchen S, Iampietro R, Woolley AM, Preston FE. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost 1999; 82 (04) 1289-1293
• 70 Kovacs MJ, Keeney M, MacKinnon K, Boyle E. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 1999; 21 (01) 55-60
• 71 de Haas S, Ghossein-Doha C, van Kuijk SMJ, van Drongelen J, Spaanderman MEA. Physiological adaptation of maternal plasma volume during pregnancy: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2017; 49 (02) 177-187
• 72 Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G. Pregnancy-associated changes in pharmacokinetics: a systematic review. PLoS Med 2016; 13 (11) e1002160
• 73 Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999; 181 (5 Pt 1): 1113-1117
• 74 Lebaudy C, Hulot JS, Amoura Z. et al. Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy. Clin Pharmacol Ther 2008; 84 (03) 370-377
• 75 Aleidan FAS, Aljarba GA, Aldakhil AA. et al. A prospective cohort study comparing achieved anti-factor Xa peak levels in pregnant and non-pregnant patients receiving therapeutic-dose low-molecular-weight heparin. Int J Hematol 2020; 112 (01) 1-7
• 76 Ensom MHH, Stephenson MD. Pharmacokinetics of low molecular weight heparin and unfractionated heparin in pregnancy. J Soc Gynecol Investig 2004; 11 (06) 377-383
• 77 Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol 2004; 191 (03) 1024-1029
• 78 Berresheim M, Wilkie J, Nerenberg KA, Ibrahim Q, Bungard TJ. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?. Thromb Res 2014; 134 (06) 1234-1240
• 79 Patel JP, Green B, Patel RK, Marsh MS, Davies JG, Arya R. Population pharmacokinetics of enoxaparin during the antenatal period. Circulation 2013; 128 (13) 1462-1469
• 80 Nichols KM, Henkin S, Creager MA. Venous thromboembolism associated with pregnancy: JACC focus seminar. J Am Coll Cardiol 2020; 76 (18) 2128-2141
• 81 Lin A, Vazquez SR, Jones AE, Witt DM. Description of anti-Xa monitoring practices during low molecular weight heparin use. J Thromb Thrombolysis 2019; 48 (04) 623-628
• 82 Hunt BJ, Gattens M, Khamashta M, Nelson-Piercy C, Almeida A. Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event. Blood Coagul Fibrinolysis 2003; 14 (08) 735-739
• 83 Mahé I, Parent F, Sanchez O. pour le groupe de travail Recommandations de bonne pratique pour la prise en charge de la MVTE [What are the special features of the treatment of venous thombo-embolic disease in the course of pregnancy and post-partum?]. Rev Mal Respir 2021; 38 (Suppl 1): e145-e152
• 84 Croles FN, Lukens MV, Mulder R, de Maat MPM, Mulder AB, Meijer K. Monitoring of heparins in antithrombin-deficient patients. Thromb Res 2019; 175: 8-12
• 85 Konstantinides SV, Meyer G, Becattini C. et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
• 86 Hirsh J, Guyatt G, Albers GW, Harrington R, Schünemann HJ. . Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008. ;133(6):110–112
• 87 Sanchez O, Benhamou Y, Bertoletti L. et al. [Recommendations of good practice for the management of thromboembolic venous disease in adults. Short version]. Rev Mal Respir 2019; 36 (02) 249-283
• 88 Levy JH, Connors JM. Heparin resistance—clinical perspectives and management strategies. N Engl J Med 2021; 385 (09) 826-832
• 89 Auditeau C, Khider L, Planquette B, Sanchez O, Smadja DM, Gendron N. D-dimer testing in clinical practice in the era of COVID-19. Res Pract Thromb Haemost 2022; 6 (04) e12730
• 90 Wang M, Lu S, Li S, Shen F. Reference intervals of D-dimer during the pregnancy and puerperium period on the STA-R evolution coagulation analyzer. Clin Chim Acta 2013; 425: 176-180
• 91 Wauthier L, Favresse J, Hardy M. et al. D-dimer testing: a narrative review. Adv Clin Chem 2023; 114: 151-223
• 92 Gutiérrez García I, Pérez Cañadas P, Martínez Uriarte J, García Izquierdo O, Angeles Jódar Pérez M, García de Guadiana Romualdo L. D-dimer during pregnancy: establishing trimester-specific reference intervals. Scand J Clin Lab Invest 2018; 78 (06) 439-442
• 93 van der Pol LM, Tromeur C, Bistervels IM. et al; Artemis Study Investigators. Pregnancy-adapted YEARS algorithm for diagnosis of suspected pulmonary embolism. N Engl J Med 2019; 380 (12) 1139-1149
• 94 Bravo-Pérez C, Vicente V, Corral J. Management of antithrombin deficiency: an update for clinicians. Expert Rev Hematol 2019; 12 (06) 397-405
• 95 Pabinger I, Thaler J. How I treat patients with hereditary antithrombin deficiency. Blood 2019; 134 (26) 2346-2353
• 96 Rodgers GM, Mahajerin A. Antithrombin therapy: current state and future outlook. Clin Appl Thromb Hemost 2023; 29: 10 760296231205279
• 97 James AH, Bates SM, Bauer KA. et al. Management of hereditary antithrombin deficiency in pregnancy. Thromb Res 2017; 157: 41-45
• 98 Lussana F, Dentali F, Abbate R. et al; Italian Society for Haemostasis and Thrombosis. Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 2009; 124 (05) e19-e25
• 99 James AH, Konkle BA, Bauer KA. Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency. Int J Womens Health 2013; 5: 233-241
• 100 Alguel G, Jochmans K, Simanek R. et al. Successful outcome in a pregnant woman with homozygous antithrombin deficiency. Thromb Haemost 2007; 98 (06) 1377-1378
• 101 Kovac M. Antithrombin deficiency in pregnancy—the unresolved issues. Lancet Haematol 2020; 7 (04) e276-e278
• 102 Leffert L, Butwick A, Carvalho B. et al; members of the SOAP VTE Taskforce. The Society for Obstetric Anesthesia and Perinatology consensus statement on the anesthetic management of pregnant and postpartum women receiving thromboprophylaxis or higher dose anticoagulants. Anesth Analg 2018; 126 (03) 928-944
• 103 Bistervels IM, Wiegers HMG, Áinle FN. et al; Highlow Investigators. Onset of labor and use of analgesia in women using thromboprophylaxis with 2 doses of low-molecular-weight heparin: insights from the Highlow study. J Thromb Haemost 2023; 21 (01) 57-67
• 104 Kietaibl S, Ferrandis R, Godier A. et al. Regional anaesthesia in patients on antithrombotic drugs: joint ESAIC/ESRA guidelines. Eur J Anaesthesiol 2022; 39 (02) 100-132
• 105 Sirico A, Saccone G, Maruotti GM. et al. Low molecular weight heparin use during pregnancy and risk of postpartum hemorrhage: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 2019; 32 (11) 1893-1900
• 106 Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106 (02) 401-407
• 107 Knol HM, Schultinge L, Veeger NJGM, Kluin-Nelemans HC, Erwich JJHM, Meijer K. The risk of postpartum hemorrhage in women using high dose of low-molecular-weight heparins during pregnancy. Thromb Res 2012; 130 (03) 334-338
• 108 Hidaka N, Hachisuga M, Tsukimori K, Onohara T, Maehara Y, Wake N. Intrapartum placement of an inferior vena cava filter for a woman with hereditary antithrombin III deficiency: its role in the prevention of fatal pulmonary embolism. J Obstet Gynaecol Res 2008; 34 (01) 95-99
• 109 Yamada T, Yamada H, Morikawa M. et al. Management of pregnancy with congenital antithrombin III deficiency: two case reports and a review of the literature. J Obstet Gynaecol Res 2001; 27 (04) 189-197
• 110 Paidas MJ, Triche EW, James AH. et al. Recombinant human antithrombin in pregnant patients with hereditary antithrombin deficiency: integrated analysis of clinical data. Am J Perinatol 2016; 33 (04) 343-349